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6Abstract1
Background & Aims: We estimated the accuracy of FibroScan vibration-controlled transient2
elastography controlled attenuation parameter (CAP) and liver stiffness measurements (LSMs)3
in assessing steatosis and fibrosis in patients with suspected NAFLD.4
5
Methods: We collected data from 450 consecutive adults who underwent liver biopsy analysis6
for suspected NAFLD at 7 centers in the United Kingdom from March 2014 through January7
2017. FibroScan examinations with M or XL probe were completed within the 2 weeks of the8
biopsy analysis (404 had a valid examination). The biopsies were scored by 2 blinded expert9
pathologists according to non-alcoholic steatohepatitis clinical research network criteria.10
Diagnostic accuracy was estimated using the area under the receiver operating characteristic11
curves (AUROC) for the categories of steatosis and fibrosis. We assessed effects of disease12
prevalence on positive and negative predictive values. For LSMs, the effects of histological13
parameters and probe type were appraised using multivariable analysis.14
15
Results: Using biopsy analysis as the reference standard, we found that CAP identified patients16
with steatosis with an AUROCs of 0.87 (95% CI, 0.82–0.92) for S≥S1, 0.77 (95% CI, 0.71–17 
0.82) for S≥S2, and 0.70 (95% CI, 0.64–0.75) for S=S3. Youden cut-off values for S≥S1, S≥S2 18
and S≥S3 were 302 dB/m, 331 dB/m and 337 dB/m respectively. LSM identified patients with19
fibrosis with AUROCs of 0.77 (95% CI, 0.72–0.82) for F≥F2, 0.80 (95% CI, 0.75–0.84) for 20 
F≥F3, and 0.89 (95% CI, 0.84–0.93) for F=F4. Youden cut-off values for F≥F2, F≥F3 and 21
F=F4 were 8.2 kPa, 9.7 kPa, and 13.6 kPa respectively. Applying the optimal cut-off values,22
determined from this cohort, to populations of lower fibrosis prevalence increased negative23
predictive values and reduced positive predictive values. Multivariable analysis found that the24
only parameter that significantly affect LSMs was fibrosis stage (P<10-16); we found no25
association with steatosis or probe type.26
27
Conclusions: In a prospective analysis of patients with NAFLD, we found CAP and LSMs by28
FibroScan to assess liver steatosis and fibrosis, respectively, with AUROC values ranging from29
0.7 to 0.89. Probe type and steatosis did not affect LSMs.30
31
KEY WORDS: VCTE, NASH, non-invasive, biomarker32
7Study registration: ClinicalTrials.gov Identifier: NCT01985009.1
Background & Aims:2
Non-alcoholic fatty liver disease is an increasingly common cause of chronic liver disease, and3
is expected to soon become the commonest indication for liver transplantation1, 2. Estimates of4
its prevalence vary from 20-40% in the general population, although only 1-3% have evidence5
of significant inflammation and fibrosis3. The presence of liver fibrosis in particular is an6
important predictor of clinical events, both in terms of overall mortality and also liver-related7
morbidities and mortality4, 5. The challenge therefore remains how to identify those individuals8
with NAFLD that have more significant pathology in a manner which is non-invasive and9
affordable by healthcare systems.10
11
Vibration-controlled transient elastography (VTCE) is one such approach which is in12
widespread clinical usage and for which there is an increasing understanding of clinically13
relevant cut-off values. By the use of a pulse-echo ultrasonic acquisition, vibration-controlled14
transient elastography (VCTE) can quantify the speed of a mechanically induced shear wave15
in liver tissue and hence generate an estimate of the degree of liver fibrosis with a liver stiffness16
measurement (LSM)6, 7. More recently this has been supplemented by the ability to quantify17
hepatic steatosis by measuring ultrasonic attenuation of the echo wave, termed the controlled18
attenuation parameter (CAP)8, 9, which has been compared to liver biopsy in prospective studies19
with the M probe10-12.20
21
Previous studies have demonstrated the limitations of the M probe in patients with an increased22
skin to liver capsular distance as can occur commonly in NAFLD and overweight/obese23
patients13, 14; there is a much higher failure rate which led to the development of the XL probe.24
8However, much of the published literature with the XL probe and CAP consists of either1
retrospective15 or small/medium prospective cohort studies16-19, with the exception of the recent2
NASH CRN studies20, 21. However, none have been the subject of large prospective powered3
diagnostic studies adhering to standards for reporting of diagnostic accuracy studies (STARD)4
guidelines22.5
6
Importantly, there are still uncertainties about the impact of other histological features on LSM7
readings with reports suggesting that steatosis may be a contributor23, 24, although these studies8
were limited in that only the M probe was used. Similarly, whilst the advent of the XL probe9
has markedly reduced the failure rate in overweight/obese individuals25, there are reports10
suggesting that cut-off ranges differ according to probe choice26.11
12
We designed a large prospective diagnostic study across 7 centres in the United Kingdom to13
evaluate the diagnostic accuracy of CAP measured either with the M or XL probe (depending14
on the FibroScan device automatic probe recommendation tool) in patients being investigated15
for potential NAFLD compared to a reference standard of histological evaluation of steatosis.16
The secondary objectives were to evaluate the diagnostic accuracy of LSM (with either M or17
XL probe) compared to a reference standard based on histological evaluation of fibrosis, and18
study of impact of histological parameters and probe type on LSM reading. In addition we19
aimed to identify cutoffs for use in clinical practice with both CAP and LSM.20
21
9Methods1
Study participant and design2
The study was a cross-sectional prospective multi-centre study, with the primary and secondary3
outcomes being to assess the diagnostic accuracy of CAP and LSM against liver histology4
which is the gold standard to evaluate the liver steatosis and fibrosis. NAFLD was suspected5
on the basis of the presence of abnormal liver enzymes in the presence of an ultrasound scan6
showing and echobright liver was the principle reason, usually in the presence of metabolic7
syndrome components. The STARD guidelines were followed to report the methods and results8
of this study22 (see Supplementary Table 1 for further details). Consecutive patients were9
prospectively recruited between March 2014 and January 2017 in 7 liver centres across the10
United Kingdom (University Hospitals Birmingham NHS Foundation Trust, Birmingham;11
Addenbrooke’s Hospital, Cambridge; Royal Free Hospital, London; Freeman Hospital,12
Newcastle upon Tyne; University Hospitals Plymouth NHS Trust, Plymouth; Queen’s Medical13
Centre, Nottingham and John Radcliffe Hospital, Oxford).14
15
The study (NCT01985009) was approved by the North Wales Research Ethics Committee16
(13/WA/0385) and by the Local Research Ethics Committee at each centre. All patients gave17
written informed consent to participate in the study. The study was conducted in accordance18
with the declaration of Helsinki and in agreement with the International Conference on19
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP). All authors had access to20
the study data and reviewed and approved the final manuscript.21
22
Main analyses: The primary outcome of the protocol was to evaluate the diagnostic accuracy23
of CAP measured either with the M or XL probe (depending on the FibroScan device automatic24
probe recommendation tool) against histological evaluation of steatosis. A secondary outcome25
10
of the protocol was to evaluate the diagnostic accuracy of liver stiffness measured either with1
M or XL probe (depending on the FibroScan device automatic probe recommendation tool)2
against histological evaluation of fibrosis.3
4
Inclusion and exclusion criteria5
Inclusion criteria were as follows: patients were ≥18 years of age, able to give written informed 6 
consent and were scheduled, independently from this study, to have a liver biopsy (LB) for7
investigation of assumed NAFLD within 2 weeks of Fibroscan examination (before or after).8
Patients were also negative for HBsAg, anti-HCV, HCV-RNA and HBVDNA. Exclusion9
criteria were as follows: patients with ascites, pregnant women, patient with any active10
implantable medical device (such as pacemaker or defibrillator), patients who had undergone11
liver transplantation, patients with cardiac failure and/or significant valvular disease, patients12
with haemochromatosis, patients that refused to undergo liver biopsy or blood tests, patients13
with an alcohol consumption above recommended limits (>14 units/week for women and >2114
units/week for men; 1 unit = 8 g of ethanol), patients with a confirmed diagnosis of active15
malignancy, or other terminal disease, patient participating in another clinical trial within the16
preceding 30 days.17
18
Patient Characteristics19
The following characteristics were recorded for each patient: age, gender, BMI, presence of20
diabetes, hypertension, and hypercholesterolemia. For each patient, a 12 hour fasting blood21
collection was performed locally on the same day of the FibroScan procedure and was then22
shipped to a central laboratory for assessment of the following laboratory parameters: platelets23
count, international normalized ratio (INR), aspartate transaminase (AST), alanine24
transaminase (ALT), gamma-glutamyl-transferase (GGT), alkaline phosphatase, albumin,25
11
bilirubin, fasting glucose, total cholesterol, high density lipoprotein (HDL) cholesterol, low1
density lipoprotein (LDL) cholesterol, triglyceride, ferritin, urea, creatinine, alpha-2-2
macroglobulin (A2M), hyaluronic acid, C-reactive protein (CRP) and cytokeratin 18 neo-3
epitope M30 (CK18-M30).4
5
Histopathologic evaluation6
Percutaneous LB was performed on all patients according to local standard procedure LB7
specimens were fixed in formalin, embedded in paraffin and stained with Hematoxylin and8
Eosin and Sirius Red for fibrosis evaluation. Slides were analysed independently by two9
experienced pathologists (PB and VP) who were blinded to each other’s reading and also to10
the patient’s clinical and Fibroscan data if available. In case of disagreement, they reviewed11
the slides together to reach consensus.12
13
Steatosis (from 0 to 3), ballooning (from 0 to 2), lobular inflammation (from 0 to 3), fibrosis14
(from 0 to 4) and NAFLD activity score (NAS) were scored using the NASH clinical research15
network (NASH CRN) scoring system 27. NASH was diagnosed using the “fatty liver:16
inhibition of progression” (FLIP) definition (presence of steatosis, hepatocyte ballooning and17
lobular inflammation with at least 1 point for each category). In addition, steatosis was semi-18
quantitatively assessed in percentage and the activity score (Ballooning (0-2) plus lobular19
inflammation (0-2)) according to the Steatosis Activity Fibrosis (SAF) was also assessed 28.20
The presence of portal inflammation was also recorded. Biopsies were categorised by the21
pathologists as normal liver (no liver pathology), NAFL (steatosis but no NASH), NASH or22
other diagnosis when no NAFLD but other histological features suggestive of another23
diagnostic were observed (e.g. granulomatous hepatitis, biliary disease, autoimmune hepatitis).24
Interpretability for liver biopsy was based on the standard criteria of length, width and lack of25
12
major fragmentation. These criteria were occasionally over-looked by the pathologist when the1
biopsy showed obvious histological criteria of NASH, septal fibrosis or cirrhosis even if the2
biopsy was small or fragmented.3
4
FibroScan liver stiffness measurement and controlled attenuation parameter5
FibroScan (Echosens, Paris, France) examination was performed in each centre by nurses or6
physicians trained and certified by the manufacturer and blinded to the patient’s histological7
evaluation. The FibroScan used in each center was a FibroScan 502 Touch model, equipped8
with both M and XL probes. An automatic probe selection tool was embedded in the device9
software which recommends the appropriate probe for each patient according to the real time10
assessment of the skin to liver capsule distance. The FibroScan examination procedure has11
been detailed previously6, 29. Briefly, all patients were asked to fast at least 3 hours prior to the12
examination, and then placed in the supine position with their right arm fully abducted.13
Measurements were performed by scanning the right liver lobe through an intercostal space.14
15
The FibroScan device simultaneously measures LSM and CAP using VCTE technology. CAP16
has been designed to measure liver ultrasonic attenuation (go and return path) at 3.5 MHz on17
both M and XL probes8, on signals acquired by the Fibroscan. The principle of CAP18
measurement has been described elsewhere8, 9, and CAP was computed only when the19
associated LSM was valid and using the same signals as the one used to measure liver stiffness.20
At the beginning of the study, CAP was not available on the XL probe, therefore, the raw21
ultrasonic radio-frequency signals were stored in the Fibroscan examination file to enable22
computation of CAP off-line. CAP computation was performed blinded to all patients’ clinical23
and histological data using the exact same configuration and algorithm to the one embedded in24
the commercial device for N=116 patients. When CAP was commercially available for the XL25
13
probe, all software were updated and the CAP value was displayed on the device screen for1
both probes during the procedure. The final CAP and LSM results were expressed in dB/m and2
kPa respectively. Only examinations with at least 10 valid individual measurements were3
deemed valid.4
5
Statistical Analysis6
Sample size estimation: Since no study had been performed previously using the probe7
recommendation on the FibroScan device, the sample size was calculated for patient measured8
with the XL probe only. It was hypothesized that approximately 1/3 of the total patients would9
be measured with M probe. Given the expected performance of CAP to detect steatosis (S≥S1) 10 
with an AUROC≥0.809, 30, 31, a projected sample size of 212 patients was deemed necessary to11
estimate an AUROC of 0.80 with the XL probe with an (1-) confidence interval,  being set12
to 5%, at a 5% standard error level, for the XL probe only. The total number of patients13
measured using both probes was set to 312 patients and the final number of patients was set at14
450 assuming a 30% drop-out rate15
16
For descriptive statistics, continuous variables were expressed as medians [interquartile range17
(IQR)] and categorical variables as absolute figures with percentages. Confidence intervals18
were reported at the 95% level. Evidence for differences between CAP and LSM between19
steatosis grades and fibrosis stages was assessed using Kruskal-Wallis test followed by Dunn's20
tests with post hoc comparison. P values of < 0.05 were considered statistically significant.21
22
Overall diagnostic accuracy of CAP and LSM was estimated as the area under the ROC curve23
(AUROC) together with its 95% confidence interval (CI). Data are reported for thresholds of24
steatosis and fibrosis. Cut-off values for CAP and LSM were identified that (a) maximise the25
14
Youden index, and also (b) at fixed values of sensitivity and specificity of 90%. For each cut-1
off value, we reported sensitivity (Se), specificity (Sp), positive predictive value (PPV),2
negative predictive value (NPV), positive likelihood ratio (LR+), negative likelihood ratio (LR-3
) together with 95% confidence intervals. In additional analyses we investigated the4
performance of the tests in settings with different prevalence using Bayes equation to estimate5
post-test probabilities from the estimated likelihood ratios. For these computations we focused6
on fibrosis thresholds of F≥F2 and F=4 which are of particular importance as they correspond 7 
with stages which result in changes in patient management. We also identified cutoffs which8
minimized the consequences of test errors across different relative weightings of false positives9
and false negatives (see Supplementary Methods).10
11
Factors influencing LSM: To evaluate the impact of histological parameters that possibly12
influenced LSM, a multivariable linear regression model was constructed with fibrosis stage,13
steatosis grade, ballooning grade, lobular inflammation and portal inflammation as candidate14
covariates and LSM as the outcome variable. In addition, the probe type used (M or XL) was15
also entered as a candidate covariate to evaluate if it had an impact on LSM when adjusted on16
histological parameters. All first order interactions were entered into the model. LSM was Box-17
Cox transformed to approximate a normal distribution. Final model selection was performed18
with a backward elimination procedure based on Bayesian information criteria (BIC). Multi-19
collinearity of independent variables was checked using the variance inflation factor. In20
addition to this multivariable analysis, LSM versus fibrosis stage stratified by probe type and21
by semi-quantitative steatosis percentage quartile was represented using a boxplot. Univariate22
analysis was performed using Kendall rank correlation coefficient between each histological23
parameter and LSM and was performed using the Mann-Whitney U test between the probe24
type and LSM.25
15
1
The sensitivity analyses on CAP and LSM diagnostic accuracy and the analyses relative to the2
influence of disease prevalence on PPV and NPV, the cutoffs which minimized the3
consequences of test errors across different relative weightings of false positives and false4
negatives and factors influencing LSM were exploratory analyses which were not pre-5
specified.6
7
For all analyses, only patients with histological results and median LSM or CAP values8
available with at least ten valid measurements were analyzed. In addition, no replacement of9
missing data has been performed. All analyses were performed using the software R, version10
3.3.032.11
12
13
16
Results1
Patient Characteristics2
The study flow chart is represented in Figure 1. Table 1 details the clinical, serological,3
histological characteristics and Fibroscan data of 383 patients with a valid FibroScan reading4
and an interpretable liver biopsy.5
6
FibroScan applicability7
Of 415 patients evaluated using the FibroScan (Figure 1), 138 (33%) were with the M probe8
and 277 (67%) with the XL probe. FibroScan readings were valid (with at least 10 valid9
individual measurements as per the manufacturer's recommendations) in 404 patients leading10
to an applicability value of 97%. For the 11 patients for whom a valid FibroScan was not11
achieved; 2 were with the M probe and 9 with the XL probe. Of note 4 of these 11 patients had12
9 valid measurements (rather than the 10 required). Patients with less than 9 valid13
measurements (n=7) had a significantly higher BMI than others (46.5 [13.6] kg.m-2 versus 36.414
[9.2] kg.m-2; P = 0.003). Within the 404 patients with valid FibroScan, patients assessed with15
the XL probe (N=268) had a significantly higher BMI than patients measured by the M probe16
(36.3 [7.8] kg.m-2 versus 29.3 [4.7] kg.m-2; P < 10-16). No adverse event has been reported17
related to the use of the FibroScan device.18
19
Liver biopsies20
A total of 412 patients underwent LB (see Figure 1: 433 eligible patients minus 16 patients21
who did not have LB, 4 patients who had LB cancelled by the investigator and 1 patient who22
withdrew consent before LB). The LB slides of 3 patients were lost during shipment and a23
further 15 LB were judged as non-interpretable by the pathologist leaving 394 (96%) as having24
an interpretable LB. A further ten patients had a LB that although interpretable by the25
17
pathologist could not be staged according to the NASH CRN scoring system. A description of1
those LB is provided in Supplementary Table 2 (2 patients being NAFLD with associated2
lesions and 8 being not NAFLD but not normal liver). Of note, 33 patients (8% of the patients3
with interpretable LB) had a histological diagnosis other than NAFLD or normal liver. A4
description of those LB is provided in Supplementary Table 2. After LB, 3 adverse events were5
reported: 1 patient had a syncopal episode following LB and pain at LB site requiring oral6
analgesia, 1 patient had hemorrhage following LB requiring hospitalization and 1 patient was7
admitted with pain and fever.8
9
Assessment of steatosis using controlled attenuation parameter10
Of 415 patients, 380 patients had an interpretable liver biopsy and valid CAP values (Figure11
1). According to histological assessment, steatosis grade distribution was as follows: S0 = 4712
(12%), S1 = 89 (23%), S2 = 107 (28%), S3 = 137 (36%) and the boxplot of CAP versus13
steatosis grade is shown in Figure 2a. CAP was significantly different between S0, S1 and S214
but not S2 and S3 (Kruskal-Wallis H = 97.70, P < 10-16; Dunn's post hoc tests, P = 0.19 between15
CAP in S2 and CAP in S3, P < 10-3 otherwise). Areas under the ROC curve (AUROC) as well16
as diagnostic performance of CAP cut-off values optimized using Youden’s index, a sensitivity17
of 90% or a specificity of 90% are detailed in Table 2 for S0 versus S1 and above, S0-S1 versus18
S2-S3 and S0-S2 versus S3. Accuracy was highest at the S≥S1 threshold, with an AUROC of 19 
0.87 (95% CI: 0.82-0.92) and sensitivity of 0.80 (0.75-0.84) and specificity of 0.83 (0.69-0.92)20
at a threshold of 302 dB/m selected by maximizing Youden’s Index. Accuracy dropped to an21
AUC of 0.77 (0.71-0.82) for the S≥S2 threshold, with the corresponding sensitivity of 0.70 22 
(0.63-0.75) and specificity of 0.76 (0.68-0.83) at the threshold of 331 dB/m maximizing23
Youden’s index and to an AUROC of 0.70 (0.64-0.75) for the S=S3 threshold with the24
corresponding sensitivity of 0.72 (0.63-0.79) and a specificity of 0.63 (0.56-0.69) at the25
18
threshold of 337 dB/m maximizing Youden’s index. The ROC plots for S≥S1, S≥S2 and S=S3 1 
are given in Supplementary Figure 1. Performance of CAP to diagnose NASH was also2
assessed. Corresponding AUC was 0.71 (0.65-0.76).3
4
The use of quality criteria based on the IQR of CAP as proposed by Caussy et al 33 and Wong5
et al 34 which recommend excluding patients with IQR of CAP greater or equal to 30 dB/m or6
40 dB/m, respectively was tested in our cohort. A large proportion of patients had an IQR of7
CAP ≥30 or 40 dB/m (57% and 39%, respectively), and performance was no better in patients 8 
with an IQR of CAP <30 or <40 dB/m (Supplementary Table 3). Indeed for the diagnosis of9
higher stages of steatosis performance was even lower in patient with an IQR of CAP <30 or10
<40 dB/m. To determine the influence of serum ALT on CAP diagnostic performance patients11
were stratified by ALT values (≤ULN, between ULN and 2xULN and >2xULN), but this did 12 
not influence CAP AUROCs (Supplementary Table 4). Performance of CAP was compared to13
the hepatic steatosis index (HSI) 35 in a subset of patients (N=375, due to 5 missing biological14
data). CAP significantly outperformed HSI for each steatosis grade S≥S1, S≥S2 and S=S3 15 
(Supplementary Table 5).16
17
Assessment of fibrosis using liver stiffness measurement18
Of the 384 patients with valid LSM and interpretable LB, only 373 had fibrosis interpretable19
according to the NASH CRN scoring system (Figure 1). Differences in characteristics between20
the 373 patients used for fibrosis staging analysis and the 10 patients with fibrosis not staged21
are given in Supplementary Table 6.22
23
Fibrosis stage distribution was as follows: F0: 62 (17%), F1: 86 (23%), F2: 85 (23%), F3: 10624
(28%), F4: 34 (9%). LSM versus fibrosis stage is presented as a boxplot in Figure 2b. LSM25
19
was significantly different between all fibrosis stages with the exception of F0 and F1 (Kruskal-1
Wallis H = 119.8, P < 10-16; Dunn's post hoc tests, P = 1 between LSM in F0 and LSM in F1,2
P < 0.05 otherwise). AUC as well as diagnostic performance of LSM cut-off values optimized3
using Youden’s index, a sensitivity of 90% or a specificity of 90% are detailed in Table 3 for4
F0-F1 versus F2 and above, F0-F2 versus F3-F4 and F0-F3 versus F4. Accuracy was highest5
at the F=F4 threshold, with an AUC of 0.89 (95% CI: 0.84-0.93) and sensitivity of 0.85 (0.69-6
0.95) and specificity of 0.79 (0.74-0.83) at a threshold of 13.6 kPa selected by maximizing7
Youden’s Index. Accuracy was lower at lower fibrosis thresholds dropping to an AUROC of8
0.80 (0.75-0.84) for F≥F3 with the corresponding sensitivity of 0.71 (0.62-0.78) and a 9 
specificity of 0.75 (0.69-0.80) at a threshold of 9.7 kPa maximizing the Youden’s index and to10
an AUROC of 0.77 (0.72-0.82) for the F≥F2 threshold, with the corresponding sensitivity of 11 
0.71 (0.64-0.77) and specificity of 0.70 (0.62-0.77) at the threshold of 8.2 kPa maximizing the12
Youden’s index. The ROC plots for F≥F2, F≥F3 and F=F4 are given in Supplementary Figure 13 
2. Performance of LSM to diagnose NASH was also assessed. Corresponding AUC was 0.6814
(0.62-0.74).15
16
The performance of the Boursier criteria36 as a quality control for Fibroscan were evaluated in17
this cohort (IQR/median<30% in patient with LSM≥7.1 kPa). Whilst 43 (12%) patients did not 18 
reach the Boursier criteria, analysis in this cohort did not find evidence that these criteria19
improved performance of Fibroscan (Supplementary Table 7) where we have assessed AUROC20
for patients reliable according to Boursier’s criteria only. The influence of ALT on LSM21
diagnostic performance was evaluated by stratifying patients on ALT values (≤ULN, between 22 
ULN and 2xULN and >2xULN). No significant influence of the effect of ALT on the LSM23
AUROC for each fibrosis stage was observed (Supplementary Table 8). The performance of24
the Baveno VI cut-offs37, in relation to patients with compensated advanced chronic liver25
20
disease with advanced fibrosis (F≥F3) were tested in this cohort. The NPV associated with the 1 
≤10 kPa cutoff was 0.80 and the PPV associated with the ≥15 kPa cutoff was 0.75. 2 
Performance of LSM was also compared to Fib438 and the NAFLD fibrosis score (NFS39).3
Diagnostic performance in terms of AUROC for each fibrosis stage (≥F2, F≥F3 and F=F4) are 4 
provided in Supplementary Table 9. LSM outperformed Fib4 and NFS for the diagnosis of5
cirrhosis and NFS for the diagnosis of F≥2. For the diagnosis of advanced fibrosis, performance 6 
of LSM was compared using the dual cut-offs (cut-off for Se≥0.90 = 7.1 kPa and cut-off for 7 
Sp≥0.90 = 14.1 kPa determined in the present cohort) against the dual cut-offs for Fib4 (1.30 8 
and 3.25)38 and NFS (-1.455 and 0.676)39. LSM had a higher Se for the confirmation of9
advanced fibrosis (F≥3) with a PPV = 0.74 (Supplementary Table 10). 10 
11
Further analysis was performed to identify cutoffs which minimized the consequences of test12
errors across different relative weightings of false positives and false negatives (see13
Supplementary Results and Supplementary Table 11). In these analyses the consequences of14
diagnostic error were explored in situations where the priority was to either avoid false positive15
diagnoses (for the diagnostic of F≥F2) or false negative diagnoses (for the diagnostic of F=F4). 16 
The analyses were performed under a range of scenarios with the cost of a false positive (FP)17
being set at 2 times, 5 times and 10 times worse than a false negative (FN) for the diagnostic18
of F≥F2. The effect on threshold is shown in Supplementary Table 11 along with the corollary 19 
analyses for the diagnostic of F=F4.20
21
Impact of fibrosis prevalence on predictive value of liver stiffness measurement22
We set out to determine the impact of fibrosis prevalence on PPV and NPV values by utilising23
a range of different pre-test probabilities values (prevalence). The prevalence figures used24
represent values from this cohort (60, 38% and 9% for F≥F2, F≥F3 and F=4 respectively) and 25 
21
also values seen in cohorts of patients with type 2 diabetes mellitus, patients at risk of liver1
disease and the general population40-42. For a diagnosis of F≥F2, F≥F3 and F=F4 there was a 2 
marked reduction in the PPV as the prevalence of fibrosis was lowered (Table 4). Rounding3
the proposed cut-offs did not affect the PPV and NPV, irrespective of prevalence (see4
Supplementary Table 12).5
6
Influence of probe type and histological parameters on liver stiffness measurement7
We next investigated the influence of probe type and histological parameters on LSM values.8
In univariate analysis, no significant difference was found between LSM and the probe type (P9
= 0.55); all histological parameters were significantly correlated to LSM: fibrosis stage ( =10
0.43, P < 10-16), ballooning grade ( = 0.22, P < 10-7), lobular inflammation grade ( = 0.21, P11
< 10-6), portal inflammation grade ( = 0.17, P < 10-4) and steatosis grade ( = 0.11, P = 0.004).12
Then, a multivariable linear regression analysis was performed. Following a backward13
selection procedure based on BIC, the only covariate influencing LSM was fibrosis stage (β =14
0.18, 95% CI = (0.15-0.21), P < 10-16). When adjusted for fibrosis stage, there was no15
significant influence of probe type or steatosis grade on the LSM value. To further illustrate16
this, a boxplot of LSM versus fibrosis stage stratified by probe type is presented in Figure 3a17
and a boxplot of LSM stratified by semi-quantitative steatosis percentage quartile is presented18
in Figure 3b.19
20
21
22
Conclusions1
This prospective study examined the association of contemporaneous VTCE and liver2
histology in a cohort of patients undergoing liver biopsy for investigation for suspected3
NAFLD, and the results were reported according to the STARD guidelines. It demonstrates the4
high applicability rate of VTCE (97%) in a large UK NAFLD cohort with BMI up to 53.25
kg/m² and provides optimised cut-off values for staging steatosis and fibrosis depending on6
prevalence and clinical context (Youden criteria, 90% sensitivity or 90% specificity). This7
study also provides novel approaches to threshold setting taking into account the prevalence of8
fibrosis in the population to be tested and also basing thresholds around clinical priorities such9
as minimising false positive diagnoses of F≥F2 or false negative diagnoses of F=4. Critically 10 
this study demonstrates that only fibrosis stage, and not probe type or any other histological11
parameters, influence LSM values.12
13
Whilst the cut-offs for steatosis grade increase progressively from S0 to S3 when set for high14
sensitivity or high specificity there is not much difference between S2 and S3 when using the15
Youden cut-off values which were 331 dB/m and 337 dB/m respectively. Nevertheless in16
clinical practice the identification of moderate steatosis is of greater utility than distinctions17
between S2 and S3, and thus the Youden cut-off for S ≥S2 of 331 dB/m is sufficient. The18
determination of steatosis by CAP is relevant for the confirmation of any degree of steatosis19
and also potentially as a serial measure in response to lifestyle or pharmacological/surgical20
intervention. The former is demonstrably feasible in this study whereas the latter will require21
examination in intervention studies.22
23
23
With regards to the association between LSM values and histological evaluation of liver1
fibrosis there is a clear demarcation between the different degrees of fibrosis for Youden cut-2
off as well as for those with high sensitivity or specificity. As expected the cut-off for liver3
cirrhosis is markedly higher at 20.9 kPa when the specificity is set at 90%. The Youden cut-off4
values from this study for F≥F2, F≥F3 and F=F4 were 8.2 kPa, 9.7 kPa, and 13.6 kPa 5
respectively, which demonstrate a clear upward increment with progressive liver fibrosis.6
These cut-off values have good sensitivity and specificity with a good PPV (0.78) for ≥F2 and 7
an excellent NPV (0.98) for F4. Distinguishing F0-F2 versus F3-4 can be achieved despite a8
slightly lower PPV (0.63), although there is a higher NPV (0.81) with the cut-off for F≥F3. 9
10
The diagnostic performance of LSM and cutoffs for stages of fibrosis in this study are broadly11
in keeping with data from a US cohort20 (Supplementary Table 13) and those recommended in12
a UK guideline43. The cutoffs from a range of other published studies are included in13
Supplementary Table 14 for comparison. Whilst reasonably similar there are some differences14
in the UK cohort such as gender (45% female vs 68% female in US cohort) and presence of15
diabetes mellitus (50% vs 44% in US cohort). For CAP however, diagnostic performance is16
higher in our cohort than in the US cohort (AUROC 0.87 (0.82-0.92) for the diagnostic of S≥1 17 
in our cohort versus 0.76 (0.64-0.89) in the US cohort. This difference may be accounted to the18
prevalence of patients with S≥S1 steatosis which is 88% in our cohort versus 95% in the US 19 
cohort. Another possibility is that the delay between FibroScan and LB was up to 12 months20
in NASH CRN study whereas in this study it was only 2 weeks.21
22
Reports have suggested that factors other than liver fibrosis, such as steatosis23, may influence23
LSM readings. To evaluate this question we performed multivariable analysis including all24
24
potentially relevant factors and notably the only factor that predicted LSM was the degree of1
liver fibrosis. Explicitly, neither the degree of steatosis or inflammation was associated with2
differences in LSM. This is likely because prior studies had not included other factors such as3
degree of fibrosis in their analyses, which when taken into account reveal that other histological4
elements do not influence LSM readings23. Also these studies only used the M probe which is5
likely to give an incorrect reading in many patients with NAFLD. Similarly, groups have6
suggested that LSM cut-offs differ according to probe choice20, 26, although in this study we7
did not find this to be the case.8
9
The threshold values will also be significantly impacted by the prevalence of the underlying10
condition. In Table 4 the effect of changing prevalence is demonstrated again allowing for11
appropriate choice of cut-off values depending on the clinical setting. This modelling data12
demonstrates that as the prevalence of liver fibrosis (≥F2 or F4) decreases there is a 13 
commensurate reduction in PPV and increase in NPV. This is relevant as cut-offs generated in14
secondary care are often applied in primary care without taking into account the marked15
difference in prevalence. In this situation a negative test would be very reassuring although a16
positive test would have a low likelihood of capturing a true positive and raises the question of17
needing further confirmatory tests.18
19
Conventional cut-off criteria for grades of steatosis and fibrosis whilst useful, do not capture20
the importance to clinical decision making and its dependence on the relevant clinical setting.21
To better model this we explored two settings; one in which the presence of ≥F2 or F4 was 22 
being tested (Supplementary Appendix). In the former setting (≥F2) the assumption was made 23 
that a false positive was two, five or ten times worse than a false negative, with concomitant24
25
increases in the threshold. In contrast for F4 the opposite view was taken, namely that it was1
more important to not miss a diagnosis (Supplementary Table 11). This allows for healthcare2
organisations to make decision depending on how they value the ratio of false positive to false3
negatives.4
5
Our study has several strengths; it is a large prospective appropriately powered study, and6
captures real world clinical practice of clinicians evaluating patients with potential NAFLD.7
By incorporating the automatic probe recommendation tool we also ensured that the correct8
probe was used to generate LSM and CAP values. It defines a number of cut-offs which can9
be used according to the clinical setting and also provides modelling data on the impact of10
prevalence on performance.11
12
A potential weakness of our study is that a number of biopsies were not interpretable as they13
did not show NAFLD but there again this is representative of real-world examination of this14
technology. In addition, we did not establish whether repeat VTCE examination would have15
generated consistent readings as demonstrated recently20.16
17
In summary, this study confirms the high applicability/low failure rate of VTCE in a cohort of18
patients with potential NAFLD, and demonstrate that LSM readings are not influenced by other19
histological components or choice of probe. Finally, our study provides a comprehensive range20
of cut-offs for LSM and CAP depending on the value a clinician places on false positive/false21
negatives as well as taking into account the prevalence of the degree of fibrosis. This will be22
critical for the roll-out of VTCE in a range of clinical settings.23
26
1
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Figure legends1
2
Figure 1. Study flow chart.3
Of 450 patients enrolled, 433 were eligible, 415 had the FibroScan examination performed and4
404 had a valid FibroScan examination. Eventually 383 had a valid controlled attenuation5
parameter (CAP) measurements and steatosis grade assessed on liver biopsy (LB) and 373 had6
a valid liver stiffness measurement (LSM) and fibrosis stage assessed on LB.7
8
Figure 2. Boxplot of (a) controlled attenuation parameter (CAP) versus steatosis grade,9
(b) liver stiffness measurement (LSM) versus fibrosis stage.10
(a) CAP values increase with increasing steatosis grade (Kruskal–Wallis test p < 10-16, Dunn's11
post hoc tests, p = 0.19 between CAP in S2 and CAP in S3, p < 10-3 otherwise); (b) LSM values12
increase significantly with increasing fibrosis stage (Kruskal-Wallis p < 10-16; Dunn's post hoc13
tests, p = 1 between LSM in F0 and LSM in F1, p < 0.05 otherwise).14
15
Figure 3. Boxplot of LSM versus fibrosis stage stratified by (a) probe type, (b) quartile of16
semi-quantitative steatosis percentage.17
The boxplot represent the LSM distribution for each fibrosis stage (a) according to the probe18
used. Patients were scanned either with the M or XL probe as proposed by the automatic probe19
recommendation tool. (b) stratified by steatosis amount: for each fibrosis stage, patients are20
stratified by steatosis quartile in the fibrosis stage.21
22
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Table legends1
2
Table 1. Patient characteristics3
4
Table 2. Diagnostic performance of controlled attenuation parameter (CAP) for steatosis5
grade greater or equal than 1, greater or equal than 2 and equal to 3.6
7
Table 3. Diagnostic performance of liver stiffness measurement (LSM) for each fibrosis8
stage greater or equal than 2, greater or equal than 3 and equal to 4.9
10
Table 4. Impact of prevalence of F≥F2 and F=4 on positive predictive value (PPV) and 11
negative predictive value (NPV) for cut-offs.12
13
14
15
16
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Table 1. Patient characteristics1
Characteristic N Distribution Range
Centre 383
Birmingham: 102 (27%)
Newcastle: 51 (13%)
London: 52 (14%)
Nottingham: 40 (10%)
Plymouth: 48 (13%)
Cambridge: 60 (16%)
Oxford: 30 (8%)
─ 
Age (years) 383 54 [18] [19-77]
BMI (kg.m-2) 383 33.8 [9.2], [19.5-53.2]
Female gender 383 171 (45%) ─ 
Diabetes mellitus 383 193 (50%) ─ 
Hypertension 383 207 (54%) ─ 
Hypercholesterolemia 383 199 (52%) ─ 
Platelets count (x109/L) 373 236 [84] [57-446]
INR 361 1.08 [0.09] [0.81-2.54]
AST (IU/L) 378 36 [25] [9-203]
ALT (IU/L) 378 50 [40] [7-298]
GGT (IU/L) 378 59 [88] [9-1718]
30
Alkaline phosphatase (IU/L) 377 82 [40] [4-738]
Albumin (g/dL) 379 4.5 [0.4] [3.6-5.5]
Bilirubin (mg/dL) 378 0.50 [0.35] [0.12-3.96]
Fasting glucose (mg/dL) 376 106 [51] [50-312]
Total cholesterol (mg/dL) 363 179 [64] [80-274]
HDL cholesterol (mg/dL) 351 43 [17] [15-101]
LDL cholesterol (mg/dL) 350 102 [51] [3-189]
Triglyceride (mg/dL) 362 161 [92] [51-501]
Ferritin (ng/mL) 378 134 [214] [7-4320]
Urea (mg/dL) 378 29 [11] [12-84]
Creatinine (mg/dL) 379 0.85 [0.22] [0.36-1.94]
A2M (mg/dL) 376 205 [121] [91-523]
Hyaluronic acid (ug/L) 379 40 [55] [19-1850]
CRP (mg/dL) 378 0.31 [0.47] [0.02-7.53]
CK18-M30 (IU/L) 369 415 [395] [74-1825]
Time between FibroScan and
liver biopsy (day)
383 0 [7] [0-14]
XL probe 383 255 (67%) ─ 
LSM (kPa), range 1.5-75 kPa 383 8.8 [7.8] [1.7-75.0]
31
CAP (dB/m), range 100-400
dB/m
380 336 [74] [100-400]
Length of liver biopsy
specimen (mm)
383 23 [10] [5-60]
Fibrosis stage 373
F0: 62 (17%)
F1: 86 (23%)
F2: 85 (23%)
F3: 106 (28%)
F4: 34 (9%)
─ 
Steatosis grade 383
S0: 47 (12%)
S1: 89 (23%)
S2: 109 (28%)
S3: 138 (36%)
─ 
Ballooning grade 383
B0: 106 (28%)
B1: 147 (38%)
B2: 130 (34%)
─ 
Lobular inflammation grade 383
I0: 90 (23%)
I1: 235 (61%)
I2: 51 (13%)
I3: 7 (2%)
─ 
NAS score 383
0-2: 90 (23%)
3-4: 122 (32%)
─ 
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5-8: 171 (45%)
Activity grade (according to
SAF)
383
A0: 55 (14%)
A1: 80 (21%)
A2: 102 (27%)
A3: 110 (29%)
A4: 36 (9%)
─ 
Portal inflammation present 382 172 (45%) ─ 
Pathologists diagnosis 383
Normal liver: 17 (4%)
NAFL: 91 (24%)
NASH: 242 (63%)
Other: 33 (9%)
─ 
Distribution is expressed as median [interquartile range] or figure (percentage).1
A2M: alpha-2 macroglobulin, ALT: alanine transaminase, AST: aspartate aminotransferase,2
BMI: body mass index, CK18-M30: cytokeratin 18 neoepitope M30, CAP: controlled3
attenuation parameter, CRP: C-reactive protein, GGT: gamma-glutamyl transferase, HDL:4
high-density lipoprotein, INR: international normalized ratio, LDL: low-density lipoprotein,5
LSM: liver stiffness measurement, NAFL: non-alcoholic fatty liver, NAFLD: NAFL disease,6
NASH: non-alcoholic steato-hepatitis, NAS: NAFLD activity score.7
8
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Table 2. Diagnostic performance of controlled attenuation parameter (CAP) for steatosis grade greater or equal than 1, greater or equal
than 2 and equal to 3.
S≥S1 (≥5% steatosis) S≥S2 (≥34% steatosis) S=S3 (≥67% steatosis) 
AUROC (95%CI) 0.87 (0.82-0.92) 0.77 (0.71-0.82) 0.70 (0.64-0.75)
Prevalence (N) 0.88 (N=303) 0.64 (N=244) 0.36 (N=137)
Youden
Index
Cut-off (dB/m) 302 331 337
Se (95%CI)
TP/(TP+FN)
Sp (95%CI)
TN/(TN+FP)
0.80 (0.75-0.84)
(266/333)
0.83 (0.69-0.92)
(39/47)
0.70 (0.63-0.75)
(170/244)
0.76 (0.68-0.83)
(104/136)
0.72 (0.63-0.79)
(98/137)
0.63 (0.56-0.69)
(152/243)
PPV (95% CI)
NPV (95% CI)
0.97 (0.94-0.98)
0.37 (0.31-0.59)
0.84 (0.78-0.88)
0.58 (0.52-0.68)
0.52 (0.45-0.62)
0.80 (0.73-0.84)
LR+ (95% CI) 4.69 (2.49-8.84) 2.96 (2.16-4.05) 1.91 (1.57-2.32)
34
LR- (95% CI) 0.24 (0.19-0.31) 0.40 (0.32-0.49) 0.46 (0.34-0.60)
Se=0.90
Cut-off (dB/m) 274 290 302
Se (95%CI)
TP/(TP+FN)
Sp (95%CI)
TN/(TN+FP)
Se = 0.90 (0.87-0.93)
(301/333)
Sp = 0.60 (0.44-0.74)
(28/47)
Se = 0.90 (0.86-0.94)
(220/244)
Sp = 0.44 (0.36-0.53)
(60/136)
Se = 0.90 (0.83-0.94)
(123/137)
Sp = 0.38 (0.32-0.44)
(92/243)
PPV (95% CI)
NPV (95% CI)
PPV = 0.94 (0.90-0.96)
NPV = 0.47 (0.38-0.62)
PPV = 0.74 (0.67-0.82)
NPV = 0.71 (0.62-0.78)
PPV = 0.45 (0.38-0.61)
NPV = 0.87 (0.79-0.90)
LR+ (95% CI)
LR- (95% CI)
LR+ = 2.24 (1.58-3.17)
LR- = 0.16 (0.11-0.24)
LR+ = 1.61 (1.38-1.88)
LR- = 0.22 (0.15-0.34)
LR+ = 1.44 (1.29-1.62)
LR- = 0.27 (0.16-0.45)
Sp=0.90
Cut-off (dB/m) 325 370 398
Se (95%CI)
TP/(TP+FN)
Se = 0.66 (0.61-0.71])
(220/333)
Se = 0.34 (0.28-0.40)
(83/244)
Se = 0.14 (0.09-0.21)
(19/137)
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Sp (95%CI)
TN/(TN+FP)
Sp = 0.90 (0.77-0.96)
(42/47)
Sp = 0.90 (0.83-0.94)
(122/136)
Sp = 0.90 (0.86-0.94)
(219/243)
PPV (95% CI)
NPV (95% CI)
PPV = 0.98 (0.95-0.98)
NPV = 0.27 (0.23-0.55)
PPV = 0.86 (0.77-0.89)
NPV = 0.43 (0.36-0.59)
PPV = 0.44 (0.34-0.56)
NPV = 0.65 (0.52-0.75)
LR+ (95% CI)
LR- (95% CI)
LR+ = 6.21 (2.70-14.27
LR- = 0.38 (0.32-0.45)
LR+ = 3.30 (1.95-5.59)
LR- = 0.74 (0.66-0.82)
LR+ = 1.40 (0.80-2.47)
LR- = 0.96 (0.88-1.03)
AUROC: area under the receiver operating curve, CI: confidence interval, FN: number of false negative, FP: number of false positive, LR-:
negative likelihood ratio, LP+: positive likelihood ratio, NPV: negative predictive value, PPV: positive predictive value, S: steatosis, Se: sensitivity,
Sp: specificity, TN: true negative, TP: true positive.
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Table 3. Diagnostic performance of liver stiffness measurement (LSM) for each fibrosis stage greater or equal than 2, greater or equal
than 3 and equal to 4.
F≥F2 F≥F3 F=F4 
AUROC (95%CI) HIS 0.80 (0.75-0.84) 0.89 (0.84-0.93)
Prevalence (N) 0.60 (N=225) 0.38 (N=140) 0.09 (N=34)
Youden
Index
Cut-off (kPa) 8.2 9.7 13.6
Se (95%CI)
TP/(TP+FN)
Sp (95%CI)
TN/(TN+FP)
Se = 0.71 (0.64-0.77)
(159/225)
Sp = 0.70 (0.62-0.77)
(103/148)
Se = 0.71 (0.62-0.78)
(99/140)
Sp = 0.75 (0.69-0.80)
(174/233)
Se = 0.85 (0.69-0.95)
(29/34)
Sp = 0.79 (0.74-0.83)
(267/339)
PPV (95% CI)
NPV (95% CI)
PPV = 0.78 (0.71-0.83)
NPV = 0.61 (0.54-0.69)
PPV = 0.63 (0.55-0.71)
NPV = 0.81 (0.74-0.85)
PPV = 0.29 (0.24-0.57)
NPV = 0.98 (0.95-0.99)
LR+ (95% CI) LR+ = 2.32 (1.80-3.01) LR+ = 2.79 (2.19-3.57) LR+ = 4.02 (3.13-5.15)
37
LR- (95% CI) LR- = 0.42 (0.34-0.53) LR- = 0.39 (0.30-0.51) LR- = 0.19 (0.08-0.42)
Se=0.90
Cut-off (kPa) 6.1 7.1 10.9
Se (95%CI)
TP/(TP+FN)
Sp (95%CI)
TN/(TN+FP)
Se = 0.90 (0.86-0.94)
(203/225)
Sp = 0.38 (0.30-0.46)
(56/148)
Se = 0.90 (0.84-0.94)
(126/140)
Sp = 0.50 (0.43-0.56)
(116/233)
Se = 0.91 (0.76-0.98)
(31/34)
Sp = 0.70 (0.64-0.74)
(236/339)
PPV (95% CI)
NPV (95% CI)
PPV = 0.69 (0.61-0.78)
NPV = 0.72 (0.62-0.78)
PPV = 0.52 (0.45-0.67)
NPV = 0.89 (0.83-0.92)
PPV = 0.23 (0.19-0.61)
NPV = 0.99 (0.96-0.99)
LR+ (95% CI)
LR- (95% CI)
LR+ = 1.45 (1.27-1.66)
LR- = 0.26 (0.17-0.40)
LR+ = 1.79 (1.56-2.06)
LR- = 0.20 (0.12-0.34)
LR+ = 3.00 (2.48-3.64)
LR- = 0.13 (0.04-0.37)
Sp=0.90
Cut-off (kPa) 12.1 14.1 20.9
Se (95%CI)
TP/(TP+FN)
Se = 0.44 (0.38-0.51)
(100/225)
Se = 0.48 (0.39-0.56)
(67/140)
Se = 0.59 (0.41-0.75)
(20/34)
38
Sp (95%CI)
TN/(TN+FP)
Sp = 0.91 (0.85-0.95)
(134/148)
Sp = 0.90 (0.86-0.94)
(210/233)
Sp = 0.90 (0.86-0.93)
(305/339)
PPV (95% CI)
NPV (95% CI)
PPV = 0.88 (0.80-0.90)
NPV = 0.52 (0.45-0.67)
PPV = 0.74 (0.65-0.80)
NPV = 0.74 (0.67-0.82)
PPV = 0.37 (0.29-0.56)
NPV = 0.96 (0.91-0.97)
LR+ (95% CI)
LR- (95% CI)
LR+ = 4.70 (2.79-7.90)
LR- = 0.61 (0.54-0.70)
LR+ = 4.85 (3.17-7.41)
LR- = 0.58 (0.49-0.68)
LR+ = 5.87 (3.83-8.97)
LR- = 0.46 (0.31-0.69)
AUROC: area under the receiver operating curve, CI: confidence interval, FN: number of false negative, FP: number of false positive, LR-:
negative likelihood ratio, LP+: positive likelihood ratio, NPV: negative predictive value, PPV: positive predictive value, Se: sensitivity, Sp:
specificity, TN: true negative, TP: true positive.
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Table 4. Impact of prevalence of F≥F2, F≥F3 and F=4 on positive predictive value (PPV) and negative predictive value (NPV) together 
with their (95% confidence interval) of LSM for the cutoff for Se=0.90, for the Youden index cutoff and for the cutoff for Sp=0.90.
Prevalence Justification Cutoff for Se=0.90 Youden index cutoff Cutoff for Se=0.90
Diagnostic
of
F≥F2 
- - Cutoff = 6.1 kPa Cutoff = 8.2 kPa Cutoff = 12.1 kPa
60%
Actual prevalence in
our population
PPV=69% (66%-71%)
NPV=72% (62%-80%)
PPV=78% (73%-82%)
NPV=61% (56%-67%)
PPV=88% (81%-92%)
NPV=52% (49%-55%)
40%
Estimated prevalence in
diabetic clinic 42
PPV=49% (46%-53%)
NPV=85% (79%-90%)
PPV=61% (54%-67%)
NPV=78% (74%-82%)
PPV=76% (65%-84%)
NPV=71% (68%-74%)
7%
Estimated prevalence in
general population 40
PPV=10% (9%-11%)
NPV=98% (97%-99%)
PPV=15% (12%-18%)
NPV=97% (96%-98%)
PPV=26% (17%-37%)
NPV=96% (95%-96%)
Diagnostic
of
F≥F3 
- - Cutoff = 7.1 kPa Cutoff = 9.7 kPa Cutoff = 14.1 kPa
38%
Actual prevalence in
our population
PPV = 52% (45%-67%)
NPV = 89% (83%-92%)
PPV = 63% (55%-71%)
NPV = 81% (74%-85%)
PPV = 74% (65%-80%)
NPV = 74% (67%-82%)
18%
Estimated prevalence in
diabetic clinic 42
PPV=28% (24%-32%)
NPV=96% (92%-98%)
PPV=38% (30%-46%)
NPV=92% (89%-94%)
PPV=52% (37%-66%)
NPV=89% (87%-91%)
2%
Estimated prevalence in
general population 41
PPV=4% (3%-4%)
NPV=99.6% (99.2%-99.8%)
PPV=5% (4%-7%)
NPV=99.2% (98.9%-99.4%)
PPV=9% (5%-15%)
NPV=98.8% (98.6%-99.1%)
Diagnostic - - Cutoff = 10.9 kPa Cutoff = 13.6 kPa Cutoff = 20.9 kPa
40
of
F=F4
9%
Actual prevalence in
our population
PPV=23% (20%-26%)
NPV=98.7% (96.5%-99.6%)
PPV=28% (24%-34%)
NPV=98.2% (96.0%-99.2)
PPV=37% (27%-47%)
NPV=95.7% (93.7%-97.1%)
3%
Estimated prevalence in
population at risk of
liver disease 41
PPV=8% (7%-10%)
NPV=99.6% (98.9%-99.9%)
PPV=11% (9%-14%)
NPV=99.4% (98.7%-99.8%)
PPV=15% (11%-22%)
NPV=98.6% (97.9%-99.1%)
1%
Estimated prevalence in
general population 41
PPV=3% (2%-4%)
NPV=99.9% (99.6%-100%)
PPV=4% (3%-5%)
NPV=99.8% (99.6%-99.9%)
PPV=6% (4%-8%)
NPV=99.5% (99.3%-99.7%)
41
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